Floatz logo

Guselkumab

PsA (Psoriatic Arthritis)

University of California, San Diegomonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the PsA (Psoriatic Arthritis) cohort.

Asset / SponsorPhaseRating
Tirzepatide
JULIO GRANADOS MONTIEL
Phase 4BBB
Ixekizumab
NHS Greater Glasgow and Clyde
Phase 3BB
Naltrexone
Brigham and Women's Hospital
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 1CC
Nivolumab
National Cancer Institute (NCI)
Phase 1CC
Bms-907351
National Cancer Institute (NCI)
Phase 1CC
Guselkumab
University of California, San Diego
N/AD
Metformin
University of Alexandria
N/AD

Same molecule, other indications

Guselkumab is also rated in:

classic familial adenomatous polyposisDormant
CC
Indicative ·
47 / 100
View asset →
celiac diseaseDormant
CC
Indicative ·
43 / 100
View asset →
psoriatic arthritisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →